November 27, 2007 Amorfix Discovers Common Link Between ALS and Alzheimer's Disease
November 15, 2007 Update from CEO
November 13, 2007 Amorfix Announces Second Quarter Fiscal 2008 Results
October 25, 2007 Amorfix Test Detects Scrapie Prions in Blood of Scrapie-Infected Sheep
October 9, 2007 Amorfix Develops Two Vaccines that Extends Life in Amyotrophic Lateral Sclerosis (ALS) Animal Model
September 20, 2007 Amorfix to Present at Workshop for vCJD Diagnostic Assays Hosted by the European Commission
August 14, 2007 Amorfix Announces First Quarter Fiscal 2008 Results
August 10, 2007 Amorfix Opens the Markets
July 25, 2007 Amorfix Commences Trading on the TSX
July 23, 2007 Amorfix to Receive Biogen's First Milestone Payment
July 17, 2007 Amorfix Receives Approval to List on the Toronto Stock Exchange
June 27, 2007 Amorfix Presents vCJD Blood Test Results from its Commercial High-Throughput Platform at The TSE Conference in Berlin
June 15, 2007 Amorfix Receives ISO13485 Certification
June 11, 2007 Amorfix Announces 2006 Results
June 7, 2007 Amorfix Recruits ALS Leader Joseph Beckman to Join Scientific Advisory Board
May 7, 2007 Amorfix's ALS Technology Published in Nature Medicine
April 24, 2007 Dr. George Adams Interviewed on BNN's "The Street - Power Breakfast"
April 2, 2007 Amorifx Reseach Featured in April Edition of CIHR Media E-Newsletter
March 23, 2007 Amorfix Provides Corporate Update on Therapeutics Program for Amyotrohpic Lateral Sclerosis (ALS or Lou Gehrig's Disease)
March 8, 2007 Amorfix Completes $10.0 Million Private Placement
February 26, 2007 Amorfix Provides Corporate Update and Announces Private Placement
February 12, 2007 Amorfix to Present vCJD Blood Test Results from Its Commerical Scale High-Throughput Platform at the Cambridge Health Institute Conference
January 10, 2007 Amorfix Announces Michael Sonnenreich as a New Director and Establishment of a Scientific Advisory Board with the Appointment of Dr. Don Cleveland